A Comprehensive 5K Plus Glycan Microarray

项目概要/摘要 聚糖阵列已被证明是研究聚糖的一个有价值的工具。相比之下，聚糖阵列给出了 在分析周转时间和财务方面，以最低的成本获得聚糖结合特异性的最佳视角 成本聚糖阵列在我们的脑海中远远没有得到很好的优化。基于阵列的 具有高通量聚糖-蛋白质相互作用谱分析的方法：1）聚糖阵列遭受系统性缺乏 2）目前的阵列提供商缺乏具有可扩展合成路线的全面聚糖文库，以及 3)生理性聚糖结合是错综复杂的，并且需要冗长的分析过程。在第一阶段，我们 试图找到解决这些限制的方法。首先，我们开发了第一种聚糖阵列， 可以分析聚糖结合亲合力而不仅仅是亲和力。其次，我们与一群精英化学家合作， 产生含有约900个聚糖结构的聚糖文库，其大于CFG的聚糖文库，并且其中之一 最大的。第三，我们与一群数据科学家和生物信息学家合作，创建了一个强大的软件， 自动化整个阵列数据分析过程的软件包。在过去的三年里，我们成立了 与研究机构、制药公司的研究人员和临床医生建立了宝贵的关系， 公共卫生部门。Z Biotech完全有能力促进供应，以满足日益增长的需求， 生物医学相关的聚糖阵列。 在这些努力中，Z Biotech真诚地感谢SBIR资助的支持。在第二阶段， 寻求资金，继续寻找解决聚糖阵列中这些关键限制的方法。一是继续 在研发方面投入巨资，以确保我们的阵列提供比竞争对手更上级的洞察力。我们还将 利用第二阶段的资金扩大生产，以满足日益增长的需求。第二，我们将与 博士格鲁吉亚州立大学的Lei Li小组。李博士是一位杰出的糖科学家， 生产复合聚糖、糖核苷酸和聚糖相关酶。在他的努力下， 我们目前的聚糖库，并在第二阶段增加约2,000个新的聚糖结构。第三，我们将完成Z Biotech的 定制软件包。在第二阶段，我们将带来第一个聚糖阵列数据分析包， 解决市场。

Project Summary / Abstract The Glycan Array has proven a valuable tool in the study of glycans. Comparatively the Glycan Array gives the greatest view of glycan binding specificity for the lowest cost in terms of analytical turn-around time and financial cost. The Glycan Array is far from well optimized in our mind. There are three key limitations to an array-based approach with high throughput glycan-protein interaction profiling: 1) glycan arrays suffer from a systematic lack of sensitivity, 2) current array providers lack comprehensive glycan libraries with scalable synthetic routes, and 3) physiological glycan binding is intricate and complex and requires a lengthy analysis process. In Phase I we sought out to find solutions for each of these limitations. First, we developed a first of its kind Glycan Array that can analyze glycan binding avidity not just affinity. Second, we partnered with an elite group of chemists to produce a glycan library containing ~900 glycan structures, which is larger than that of the CFG and one of the largest ever. Third, we partnered with a group of data scientists and bioinformaticians to create a robust software package that automates the entire array data analysis process. Over the last three years we have formed valuable relationships with researchers and clinicians in research institutes, pharmaceutical companies and public health sectors. Z Biotech is perfectly positioned to facilitate the supply for increasing demand for biomedically relevant glycan arrays. In each of these endeavors Z Biotech sincerely thanks to the support of this SBIR grant. Now in Phase II we are seeking funds to continue to find solutions for these key limitations in Glycan Array. First, we will continue to invest heavily in R&D to ensure that our arrays offer superior insights compared to our competitors. We will also use funds from Phase II to scale up production to accommodate increasing demand. Second, we will team with Dr. Lei Li’s group at Georgia State University. Dr. Li is an outstanding glyco-scientist with experience in production of complex glycans, sugar nucleotides and glycan-related enzymes. With his effort we will maintain our current glycan library and add ~2,000 new glycan structures in Phase II. Third, we will complete Z Biotech’s custom software package. In Phase II we will bring this first of its kind glycan array data analysis package or solution to market.